TY - BOOK ID - 86209389 TI - Fast Facts : CAR T-cell therapy in diffuse large B-cell lymphoma : a practical resource for nurses AU - Buka, R. J. AU - Moloney, Deirdre PY - 2021 SN - 3318069353 PB - Abingdon, Oxford : S. Karger Publishers Ltd, DB - UniCat KW - B cells KW - T cells. KW - Cancer KW - Lymphoma, Large B-Cell, Diffuse KW - Receptors, Chimeric Antigen KW - Immunotherapy, Adoptive KW - Tumors KW - Treatment. KW - Nursing. KW - therapy. KW - therapeutic use. KW - methods. KW - adverse effects. KW - Cancer nursing KW - Oncology nursing KW - T lymphocytes KW - Thymus-dependent cells KW - Thymus-dependent lymphocytes KW - Thymus-derived cells KW - Lymphocytes KW - B lymphocytes KW - Bone marrow derived cells KW - Bursa equivalent cells KW - Antigen presenting cells KW - Oncology Nursing UR - https://www.unicat.be/uniCat?func=search&query=sysid:86209389 AB - Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine.Table of Contents:•DLBCL: an overview•CAR T cells•CAR T-cell products•Delivering CAR T-cell therapy and managing patient expectations•CAR T-cell therapy-related toxicities ER -